Ocular Therapeut Stock Price, News & Analysis

Ocular Therapeutix (NASDAQ: OCUL) announced the first patient randomized in HELIOS-3, the second Phase 3 registrational trial for AXPAXLI (OTX-TKI) in non-proliferative diabetic retinopathy (NPDR) on Nov 24, 2025. HELIOS-2 and HELIOS-3 are complementary global superiority studies using a novel ordinal ≥2-step diabetic retinopathy severity score (DRSS) primary endpoint, with primary assessment at Week 52. HELIOS-2 compares AXPAXLI dosed every 12 months to ranibizumab 0.3 mg; HELIOS-3 compares 6- and 12-month AXPAXLI regimens to sham. Ocular secured an SPA alignment with the FDA on the novel DRSS endpoint for HELIOS-2 and is targeting a broad DR label by including patients with non-center-involved DME (non-CI-DME).

Ocular Therapeutix (NASDAQ: OCUL) will participate in investor conferences in November and December 2025 with fireside chats by Pravin U. Dugel, MD, Executive Chairman, President and CEO.

Event details: Jefferies Global Healthcare Conference in London — Tuesday, November 18, 2025, 2:30–2:55 PM GMT; Piper Sandler 37th Annual Healthcare Conference in New York — Wednesday, December 3, 2025, 8:30–8:55 AM ET. Live webcasts will be available on the company's Investor Relations Events and Presentations page, and replays will be archived for at least 30 days after each presentation.

Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to a newly hired non-executive employee under its 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The grants, effective November 3, 2025, include a non-statutory stock option for 1,100 shares at an exercise price of $11.47 (the closing price on the grant date) with a 10-year term and four-year vesting (25% vesting on October 20, 2026, then monthly over three years), and a restricted stock unit award for 367 shares vesting in equal annual installments over three years beginning November 3, 2026. Awards are subject to the award agreements and plan terms.

Ocular Therapeutix (NASDAQ: OCUL) reported Q3 2025 results and program milestones on Nov 4, 2025. The company held $344.8 million cash as of Sept 30, 2025 and closed an equity offering in Oct 2025 with approximately $445 million net proceeds, providing projected runway into 2028.

Clinical progress: the SOL-R wet AMD registrational trial achieved target randomization of 555 subjects (topline on track for 1H 2027); SOL-1 superiority trial remains on track for Q1 2026 topline with >95% retention; HELIOS Phase 3 program in NPDR is imminent and has an SPA-aligned novel ordinal DRSS endpoint. Q3 revenue was $14.5M (down 5.8% YoY) with a net loss of $69.4M (−$0.38 per share).

Ocular Therapeutix (NASDAQ: OCUL) announced that its Phase 3 SOL-R trial of AXPAXLI (OTX-TKI) in wet age-related macular degeneration has reached its target randomization of 555 subjects. SOL-R compares AXPAXLI every 6 months versus aflibercept (2 mg) every 8 weeks across ~100 sites in the U.S., Argentina, India and Australia, with a Week 56 primary endpoint for mean change in BCVA and 90% power to a non-inferiority margin of -4.5 letters. Topline data remain on track for 1H 2027. Together with SOL-1 (single-injection superiority study; topline expected Q1 2026), these trials could support a potential NDA for AXPAXLI if both readouts are positive.

Ocular Therapeutix (NASDAQ: OCUL) announced it will report third quarter 2025 financial results and host a conference call and webcast on Tuesday, November 4, 2025 at 8:00 AM ET.

Participant dial-in numbers are U.S.: 1-877-407-9039 and International: 1-201-689-8470. A live webcast will be available on the company’s Investor Relations Events and Presentations page, and a replay will be archived for at least 30 days.

Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple scientific conferences in October 2025 to present clinical and company data on retina therapies.

Key appearances: American Academy of Optometry (Boston, Oct 8–11) — poster on one‑year HELIOS Phase 1 OTX‑TKI safety and efficacy on Oct 9, 4:30–6:30 PM ET by Trung Tran; Eyecelerator @ AAO (Orlando, Oct 16) — company showcase by Peter K. Kaiser, MD on Oct 16, 1:15–2:45 PM ET; American Academy of Ophthalmology (Orlando, Oct 18–20) — on‑demand poster on macular fluid and vascular leakage after a single axitinib intravitreal hydrogel, presented by Margaret Chang, MD, MS. Exact times may change.

Ocular Therapeutix (NASDAQ: OCUL) has announced the pricing of an underwritten public offering of 37,909,018 shares of common stock at $12.53 per share, aiming to raise approximately $475.0 million in gross proceeds.

The proceeds will fund several key initiatives, including the open-label extension study for AXPAXLI™ in wet AMD patients, Phase 3 clinical trials for non-proliferative diabetic retinopathy treatment, infrastructure investments, manufacturing support, and pre-commercialization activities for AXPAXLI. The offering is expected to close around October 1, 2025.

BofA Securities, TD Cowen, and Piper Sandler & Co. are serving as joint book-running managers, with Baird and Raymond James as lead managers, and Citizens Capital Markets and H.C. Wainwright & Co. as co-managers.

Ocular Therapeutix (NASDAQ:OCUL) is hosting an Investor Day to showcase progress in their retinal disease programs. The company's lead candidate AXPAXLI™ is advancing in two key areas:

In wet AMD, the SOL-1 superiority trial shows >95% patient retention with topline data expected in Q1 2026, while the SOL-R non-inferiority trial is on track for H1 2027 results. Both trials could support the first superiority label versus aflibercept.

For diabetic retinopathy, Ocular announced two new Phase 3 trials: HELIOS-2 and HELIOS-3, featuring a novel FDA-aligned ordinal endpoint measuring both disease improvement and prevention of worsening. HELIOS-2 will evaluate 432 patients comparing AXPAXLI to ranibizumab, while HELIOS-3 will study 930 patients across three treatment arms.